Experts warn against the fast-track approval of leucovorin, a $2.50 pill, for symptoms associated with autism spectrum disorders, stressing the need for caution in treatment.
- The American Academy of Pediatrics announced that leucovorin, also known as Folinic acid, is not recommended for routine use in children with autism spectrum disorders.
- Leucovorin, derived from folate, has been used since the 1950s primarily for cancer patients, raising concerns about its efficacy in treating autism spectrum symptoms.
- The Food and Drug Administration is currently fast-tracking the approval process for leucovorin, which has sparked debate among doctors about its potential risks and benefits.
Why It Matters
This caution underscores the importance of rigorous evaluation of treatments for autism spectrum disorders, especially as new therapies emerge, impacting how families and healthcare providers approach autism management.